OR WAIT null SECS
November 10, 2017
As part of Recipharm’s ongoing initiative to improve profitability and competitiveness, a decision has been made to end operations in Stockholm and Höganäs.
The authors of the study believe it could have significant implications for the discovery of new dermatological products for major diseases such as psoriasis.
November 09, 2017
The company has officially opened a local brand office in South Korean to support its existing business in the region.
November 07, 2017
The debate continues over biosimilar naming, interchangeability, and patent protection, as well as lingering concerns in the medical community about the safety of switching patients to new therapies.
November 03, 2017
The Human Vaccines Project has created the Universal Influenza Vaccine Initiative, a research program that will aim to understand the human immune system’s role in the development of universal influenza vaccines.
CDMO Celonic acquired a biomanufacturing facility in Heidelberg, Germany from Glycotope.
November 02, 2017
The companies will collaborate to develop and manufacture Grid’s lead therapeutic candidate for the treatment of solid tumors.
Ralph Gosden, head of product development at Catalent’s Swindon, United Kingdom site, explains the opportunities of orally disintegrating tablets as a patient-centric dosage form.
Pharmaceutical companies are increasingly adopting patient-centric formulation development to ensure that drug products adequately meet the needs of end-users in all target patient populations.
Taste masking increases drug acceptability and medication adherence in pediatric, geriatric, and other special patient populations.
